Obesity

Low awareness of GLP-1s globally, but high in the most advanced economies
Healthcare Survey

Low awareness of GLP-1s globally, but high in the most advanced economies

Despite media discussions around the drugs, only around a third across 30 countries have heard about the drugs, with a lot of the discourse taking place via social media according to the Ipsos Health Service Report.
Ipsos Launches GLP-1 PersonaBot, Designed to Support Companies’ Understanding of the Consumer Obesity Treatment Market
Healthcare Publication

Ipsos launches GLP-1 PersonaBot, designed to support companies’ understanding of the consumer obesity treatment market

Ipsos’ latest AI-powered innovation offers unparalleled insights into the fast-moving consumer obesity treatment market – while reinforcing Ipsos’ position at the forefront of AI applications in market research.
Healthcare Vs Evolution: Can GLP-1s Rewrite Our Evolutionary Story?
Healthcare Publication

Healthcare vs Evolution: Can GLP-1s Rewrite Our Evolutionary Story?

Our evolutionary tale began 6 million years ago, when humans were programmed to hoard calories in a world of scarcity. Today, that ancient wiring has become our greatest health risk.
Ipsos Update – December 2024
Ipsos Update Publication

Ipsos Update – December 2024

Security, Inflation, Perils of Perception … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.
GLP–1s: A Healthcare Revolution? - Ipsos
Healthcare Publication

GLP–1s: A Healthcare Revolution?

One of this century’s biggest game-changers will likely be a novel drug class that’s showing unprecedented success, or the promise of it, in treating some of the world’s most prevalent conditions.